Annual report
3583.TEDINET S100ODMS
Period2021-04-01 → 2022-03-31
Filed2022-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥5.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥707m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥265m | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥727m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥332m | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥203m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥429m | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥274m | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥726m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥224m | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥537m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥115m | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥141m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥318m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥184m | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥537m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥115m | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥9.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥8.6bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.5bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.0bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.8bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥4.7bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.5bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.9bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.4bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥631m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥279m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥509m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥451m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥189m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥182m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥139m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥173m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥383m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥266m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥89m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥339m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥115m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥194.04 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.6 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.89 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.17 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.79 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,957.25 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,753.19 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,724.32 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,708.06 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,619.49 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 57.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.1% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.5% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 10.5% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 364 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 350 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 423 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 424 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 390 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥5.3bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥4.6bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥5.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.0bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥571m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥213m | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥619m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥246m | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥132m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥337m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥202m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥616m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥270m | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥440m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥190m | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥95m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥250m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥140m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.7bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥8.0bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥7.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.8bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.9bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.7bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥4.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.4bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.0bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.5bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥159.25 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.67 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.29 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.69 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.8 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,736.4 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,580.8 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,533.57 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,525.76 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,458.53 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 55.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.4% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.6% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,092,623 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 132 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 130 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 129 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 131 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 128 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 81
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥299,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥14m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥12m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥36m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥20m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥3m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥12m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥306m |
| Medical Productsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥64m |
| Medical Productsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥48m |
| Medical Productsreportable segment | employees | at 2022-03-31 | 63 pure |
| Medical Productsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥4m |
| Medical Productsreportable segment | segment assets | at 2022-03-31 | ¥1.4bn |
| Medical Productsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥147m |
| Technological Productsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥220m |
| Technological Productsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥229m |
| Technological Productsreportable segment | employees | at 2022-03-31 | 288 pure |
| Technological Productsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥4.1bn |
| Technological Productsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥4.1bn |
| Technological Productsreportable segment | segment assets | at 2022-03-31 | ¥5.7bn |
| Technological Productsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥886m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥284m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥277m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥4m |
| —segment total | segment assets | at 2022-03-31 | ¥7.1bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥284m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥277m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥16m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥7.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2020-04-01 → 2021-03-31 | ¥665,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2020-04-01 → 2021-03-31 | ¥13m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2020-04-01 → 2021-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥9m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2021-03-31 | ¥25m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2020-04-01 → 2021-03-31 | −¥10m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥14m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥16m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥1.8bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥272m |
| Medical Productsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥31m |
| Medical Productsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥40m |
| Medical Productsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥7m |
| Medical Productsreportable segment | segment assets | at 2021-03-31 | ¥1.3bn |
| Medical Productsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥142m |
| Technological Productsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥120m |
| Technological Productsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥228m |
| Technological Productsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥3.3bn |
| Technological Productsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥3.3bn |
| Technological Productsreportable segment | segment assets | at 2021-03-31 | ¥5.6bn |
| Technological Productsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥407m |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥151m |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥267m |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥4.8bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥4.7bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥7m |
| —segment total | segment assets | at 2021-03-31 | ¥6.9bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥548m |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥268m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥4.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥4.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥16m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥6.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥538m |
| Medical Productsreportable segment | employees | at 2022-03-31 | 15 pure |
| Technological Productsreportable segment | employees | at 2022-03-31 | 104 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,600
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 70 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 62 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 65 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.771 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.737 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.532 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.565 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.784 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.159 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.100 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.996 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.415 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.443 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 288 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 85 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 63 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 90 | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 13 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | － | |
| Number of employees | CurrentYearInstant | 364 | |
| Average number of temporary workers | CurrentYearInstant | 175 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 132 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 46.0 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 17.1 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 4992000 | JPY |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 65 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 104 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 64 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 15 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 13 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 132 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 65 | |
| Research and development expenses research and development activities | CurrentYearDuration | 122000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 82000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 39000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 281000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 217000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 63000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 3092623 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 3092623 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 3092623 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 3092623 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 6 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 11 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |